Drug Detail

Information about Vorinostat + Bortezomib

Generic Name
IND	Vorinostat + Bortezomib
Brand Name (US)
Manufacturer
Drug Type
Delivery	Oral, Intravenous
Approval Status	This combination is in phase 3 for non-GIST cancers
Indications
Overall Strategy	GIST cell based
Strategy	Inhibit protein translation + Unblock cell death genes
Drug Category	HDAC inhibitor + Proteasome inhibitor

This drug combination is being tested in various tumor types, but not in GIST. Vorinostat is an HDAC inhibitor and bortezomib is a proteasome inhibitor. Both drugs are approved for non-GIST applications.